Kacirova Ivana, Grundmann Milan, Brozmanova Hana
Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic; Department of Clinical Pharmacology, Department of Laboratory Diagnostics, University Hospital Ostrava, 17. listopadu 1790, 708 52 Ostrava, Czech Republic.
Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00 Ostrava, Czech Republic.
Epilepsy Res. 2016 May;122:84-90. doi: 10.1016/j.eplepsyres.2016.02.013. Epub 2016 Mar 2.
Carbamazepine is one of the three most frequently prescribed antiepileptic drugs in pregnancy. However, data relating to both carbamazepine and carbamazepine-10,11-epoxide transplacental passage remain sparse.
We have analysed in a cohort of 114 women carbamazepine and carbamazepine-10,11-epoxide levels in maternal and umbilical cord serum at birth during 25 years retrospectively. The carbamazepine maternal apparent oral clearance, ratio of the umbilical cord/maternal level and ratio of the carbamazepine-10,11-epoxide/carbamazepine ratio were estimated. The influence of co-medication with valproic acid or enzyme-inducing antiepileptic drugs was evaluated.
The maternal carbamazepine levels varied from 0.6 to 11.8mg/L (carbamazepine-10,11-epoxide 0.1-2.5mg/L) and in umbilical cord between 0.1 and 10.5mg/L (carbamazepine-10,11-epoxide 0.1-2.2mg/L). The ratio the of umbilical cord/maternal level of carbamazepine ranged from 0.03 to 2.23 (median 0.80) and of carbamazepine-10,11-epoxide between 0.17 and 2.00 (median 0.83). Concomitant administration with enzyme inducers significantly increased the maternal apparent oral clearance by approximately 50% and co-administration with valproic acid approximately by 70%. Combination with valproic acid significantly increased the rate of carbamazepine-10,11-epoxide to the parent drug both in maternal serum (by approximately 80%) and in umbilical cord (by 100%).
The data showed the wide interindividual variability of the ratio of the umbilical cord/maternal level of both carbamazepine and carbamazepine-10,11-epoxide. It is the first study showing the significant increase of the ratio of umbilical cord/maternal level of carbamazepine-10,11-epoxide and carbamazepine-10,11-epoxide/carbamazepine ratio not only in maternal serum but also in umbilical cord in addition of valproic acid. The present study demonstrates that a concomitant administration of enzyme-inducing antiepileptics and valproic acid increases the maternal apparent oral clearance of carbamazepine significantly.
卡马西平是孕期最常处方的三种抗癫痫药物之一。然而,关于卡马西平和卡马西平 - 10,11 - 环氧化物经胎盘转运的数据仍然稀少。
我们回顾性分析了114名女性在25年间分娩时母体和脐带血清中的卡马西平和卡马西平 - 10,11 - 环氧化物水平。估算了母体卡马西平的表观口服清除率、脐带/母体水平比值以及卡马西平 - 10,11 - 环氧化物/卡马西平比值。评估了与丙戊酸或酶诱导性抗癫痫药物联合用药的影响。
母体卡马西平水平在0.6至11.8mg/L之间(卡马西平 - 10,11 - 环氧化物为0.1至2.5mg/L),脐带中为0.1至10.5mg/L(卡马西平 - 10,11 - 环氧化物为0.1至2.2mg/L)。卡马西平的脐带/母体水平比值在0.03至2.23之间(中位数为0.80),卡马西平 - 10,11 - 环氧化物的比值在0.17至2.00之间(中位数为0.83)。与酶诱导剂同时给药显著增加母体表观口服清除率约50%,与丙戊酸同时给药约增加70%。丙戊酸联合用药显著增加了母体血清(约80%)和脐带(100%)中卡马西平 - 10,11 - 环氧化物与母体药物的比率。
数据显示卡马西平和卡马西平 - 10,11 - 环氧化物的脐带/母体水平比值存在广泛的个体间差异。这是第一项表明不仅在母体血清中,而且在脐带中,丙戊酸会显著增加卡马西平 - 10,11 - 环氧化物的脐带/母体水平比值以及卡马西平 - 10,11 - 环氧化物/卡马西平比值的研究。本研究表明,酶诱导性抗癫痫药物与丙戊酸联合给药会显著增加母体卡马西平的表观口服清除率。